AmgenXTER:AMG +1.97%91 EBITDA Margin % is 44.76% as of Mar. 2026, which is 14% below its 10-year median of 51.81. GuruFocus rates XTER:AMG with a GF Score™ of 91/100 and a GF Value™ of €310.77 (Fairly Valued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Amgen ranks better than 95.71% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Amgen's EBITDA for the
three
months ended in Mar. 2026 was €3,336 Mil. Amgen's Revenue for the
three
months ended in Mar. 2026 was €7,455 Mil. Therefore, Amgen's EBITDA margin for the quarter that ended in Mar. 2026 was 44.76%.
Amgen (XTER:AMG) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Amgen EBITDA Margin % Related Terms
Amgen EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Amgen's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:AMG vs GILD, PFE, BMY: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Amgen's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Amgen's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (XTER:AMG) has a EBITDA Margin % of 44.76% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amgen and its competitors. This is 14% below median its historical median of 51.81. Over the past decade, Amgen's EBITDA Margin % has ranged from 39.96 to 56.27. According to the industry distribution chart, Amgen ranks #41 out of 955 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Amgen's EBITDA Margin % too high?
Amgen's current EBITDA Margin % of 44.76% is 14% below median its 10-year median of 51.81. Over the past 10 years, this metric has ranged from a low of 39.96 to a high of 56.27. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Amgen's value of 44.76% is 261.3% above this industry median. Based on the distribution chart, Amgen ranks #41 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amgen has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's EBITDA Margin % compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #41 out of 955 companies for EBITDA Margin %. This places Amgen in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Amgen's value of 44.76% is 261.3% above this benchmark. Historically, Amgen's own EBITDA Margin % has ranged from 39.96 to 56.27 over the past decade. While the company's 10-year median is 51.81 vs. the industry median of 12.39, Amgen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current EBITDA Margin % of 44.76% is 261.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current EBITDA Margin % is 44.76%, which is 14% below median its own 10-year median of 51.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (XTER:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €310.77, compared to a current price of €305.05 — trading 1.8% below its estimated fair value. The current EBITDA Margin % is 44.76%, which is 14% below median its 10-year median of 51.81 and 261.3% above the Drug Manufacturers industry median of 12.39. Amgen's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Amgen (XTER:AMG), the current EBITDA Margin % is 44.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (XTER:AMG) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €305.05 is trading 1.8% below its estimated GF Value™ of €310.77.
GuruFocus considers Amgen to be Fairly Valued.
Key valuation signals for XTER:AMG:
EBITDA Margin %: 44.76% (14% below median its 10-year median of 51.81)
GF Value™: €310.77 vs. price of €305.05 (1.8% below fair value)
Industry Position: 261.3% above the Drug Manufacturers median (#41 of 955)
No single metric tells the full story. See the XTER:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
91GF Score
Get the complete analysis for XTER:AMG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:AMG has been successfully added to your 
